What are the clinical manifestations of heart failure in adults, and how are natriuretic peptides utilized in its diagnosis and management?

Heart Failure: Clinical Manifestations and Diagnosis Using Natriuretic Peptides

Use natriuretic peptides (BNP or NT-proBNP) as your primary rule-out test in acute care settings when heart failure is suspected—a BNP <100 pg/mL or NT-proBNP <300 pg/mL reliably excludes acute heart failure with near-perfect sensitivity, allowing you to rapidly investigate alternative causes of symptoms. 1

Clinical Manifestations of Heart Failure

Heart failure presents with symptoms and signs caused by structural or functional cardiac abnormalities, requiring at least one of: elevated natriuretic peptides OR objective evidence of cardiogenic pulmonary/systemic congestion 2.

Key clinical features to identify:

• Symptoms of congestion: Dyspnea (at rest or with exertion), orthopnea, paroxysmal nocturnal dyspnea, weight gain, fatigue
• Signs of volume overload: Elevated jugular venous pressure, peripheral edema, pulmonary rales, hepatomegaly, ascites
• Adequacy of perfusion: Cool extremities, altered mental status, decreased urine output, hypotension (indicating cardiogenic shock requiring immediate intervention) 3

Critical precipitating factors to assess immediately:

• Acute coronary syndrome/ischemia (obtain ECG and troponin)
• Severe hypertension
• Atrial or ventricular arrhythmias
• Infections
• Pulmonary embolism
• Renal failure
• Medical or dietary noncompliance 3

Diagnostic Use of Natriuretic Peptides

In Acute Care Settings (Emergency Department/Hospital)

Rule-out thresholds (excellent sensitivity ~95-99%):

• BNP <100 pg/mL excludes acute heart failure 1, 4
• NT-proBNP <300 pg/mL excludes acute heart failure 1
• For NT-proBNP, age-adjusted cutoffs may be used: <450 pg/mL for patients <50 years, <900 pg/mL for patients ≥50 years 4

Rule-in thresholds (modest specificity, requires confirmation):

• BNP ≥100 pg/mL or NT-proBNP ≥300 pg/mL raises suspicion but requires echocardiography to confirm diagnosis 1

The diagnostic accuracy of BNP at 100 pg/mL cutoff shows 90% sensitivity, 76% specificity, and 81% overall diagnostic accuracy—superior to clinical assessment alone 4. Both BNP and NT-proBNP perform equivalently; use whichever is locally available 1.

In Outpatient/Ambulatory Settings

For chronic or suspected heart failure:

• BNP <35 pg/mL or NT-proBNP <125 pg/mL excludes heart failure 5, 3
• Values above these thresholds warrant further cardiac evaluation with echocardiography

Critical Interpretation Caveats

Elevated natriuretic peptides occur in non-cardiac conditions—always correlate with clinical context:

• Pulmonary embolism
• Sepsis
• Renal failure (significantly elevates levels)
• Advanced age (increases baseline levels)
• Atrial fibrillation

Falsely low natriuretic peptides occur with:

• Obesity (adipose tissue clears natriuretic peptides, reducing sensitivity in morbidly obese patients) 6, 1
• Flash pulmonary edema (insufficient time for peptide elevation)

Do NOT order natriuretic peptides when:

• Clinical scenario clearly indicates heart failure (e.g., known HF with obvious decompensation)
• Alternative diagnosis is certain (e.g., trauma-related dyspnea) 1

Management Applications

Confirming Diagnosis

Once natriuretic peptides suggest heart failure, echocardiography is mandatory to:

• Confirm diagnosis
• Determine ejection fraction phenotype (HFrEF ≤40%, HFmrEF 41-49%, HFpEF ≥50%) 2
• Identify structural abnormalities
• Guide therapeutic decisions 1

Prognostic Value

Elevated natriuretic peptides predict:

• Increased mortality risk
• Higher hospitalization rates
• Major cardiovascular events 6, 7

However, insufficient evidence exists to recommend routine serial natriuretic peptide measurements for guiding therapy adjustments in established heart failure 6. The data on natriuretic peptide-guided therapy remains equivocal for improving mortality and cardiovascular outcomes.

Special Consideration: ARNI Therapy

Important: Sacubitril/valsartan (ARNI) increases BNP levels but decreases NT-proBNP levels. Use NT-proBNP for monitoring patients on ARNI therapy, not BNP 6.

Practical Algorithm

For acute dyspnea of uncertain etiology:

1. Obtain natriuretic peptide (BNP or NT-proBNP) immediately in emergency department
2. If BNP <100 pg/mL or NT-proBNP <300 pg/mL: Heart failure excluded—investigate alternative diagnoses
3. If above threshold: Proceed urgently to echocardiography while initiating treatment for presumed heart failure (IV loop diuretics, oxygen if hypoxemic) 3
4. Exclude non-cardiac causes of elevated natriuretic peptides through clinical assessment

For outpatient screening in high-risk patients (diabetes, hypertension, obesity):

1. Measure BNP or NT-proBNP
2. If BNP <35 pg/mL or NT-proBNP <125 pg/mL: Heart failure unlikely
3. If elevated: Refer for echocardiography and cardiology evaluation 8, 9

The 2015 BMJ meta-analysis 1 represents the highest quality evidence, demonstrating that natriuretic peptides reliably exclude acute heart failure, reduce time to diagnosis, shorten hospital stays, and potentially reduce mortality through earlier appropriate treatment initiation.